Guillemette Clément
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guillemette Clément has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Mathilde Renaud
Service de Neurologie, Centre Hospitalier Universitaire Régional de Nancy, Nancy, France
3 shared publicationsArmand Hocquel
Service de neurologie, centre hospitalier régional universitaire de Nancy, hôpital Central, Nancy, France
2 shared publicationsBernard Brais
Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Canada
2 shared publications- Bernard Brais
Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Canada
2 shared publications Carine Pourié
INSERM-U1256 NGERE, Université de Lorraine, Nancy, France
2 shared publicationsCéline Bonnet
INSERM-U1256 NGERE, Université de Lorraine, Nancy, France
2 shared publications
Latest Publications
- 1 August 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 543-560
Alzheimer's disease and nutrition: Focus on the impact of hyperhomocysteinemia
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease. Despite advances in the understanding of the genetics of AD, environmental risk factors are still under investigation, and the etiology is still not completely understood. The environmental component of AD, which we explore in the first part of this review, takes on greater importance with more advanced disease onset. Moreover, genetics does not explain all of AD. Environmental risk factors are divided into modifiable and nonmodifiable risk factors. Among the modifiable risk factors, nutrition seems to play a predominant role. One-carbon metabolism (OCM) is involved in this food-related component, notably through B vitamins. Homocysteine, a sulfur-containing amino acid, is at the crossroads of OCM. Abnormal increases in homocysteine levels (hyperhomocysteinemia) are associated with deleterious effects on cognition. Various mechanisms can lead to hyperhomocysteinemia, including genetic factors associated with different polymorphisms, dietary deficiencies targeting vitamins B9 and B12, and renal insufficiency. The second part of the review details OCM and the role of homocysteine. Finally, part 3 highlights the numerous studies in the literature describing the association between hyperhomocysteinemia and cognitive decline. However, the mechanistic links between hyperhomocysteinemia and cognitive decline in AD are poorly understood. Several hypotheses have been proposed in the literature. The toxic effects of homocysteine could be mediated by N-homocysteinylation, a nonenzymatic reaction leading to the irreversible accumulation of N-homocysteinylated proteins. Finally, we detail some therapeutic trials targeting one-carbon metabolism in AD, notably vitamin B9 and B12 supplementation.
- 1 August 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (2) , 543-560
Alzheimer's disease and nutrition: Focus on the impact of hyperhomocysteinemia
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease. Despite advances in the understanding of the genetics of AD, environmental risk factors are still under investigation, and the etiology is still not completely understood. The environmental component of AD, which we explore in the first part of this review, takes on greater importance with more advanced disease onset. Moreover, genetics does not explain all of AD. Environmental risk factors are divided into modifiable and nonmodifiable risk factors. Among the modifiable risk factors, nutrition seems to play a predominant role. One-carbon metabolism (OCM) is involved in this food-related component, notably through B vitamins. Homocysteine, a sulfur-containing amino acid, is at the crossroads of OCM. Abnormal increases in homocysteine levels (hyperhomocysteinemia) are associated with deleterious effects on cognition. Various mechanisms can lead to hyperhomocysteinemia, including genetic factors associated with different polymorphisms, dietary deficiencies targeting vitamins B9 and B12, and renal insufficiency. The second part of the review details OCM and the role of homocysteine. Finally, part 3 highlights the numerous studies in the literature describing the association between hyperhomocysteinemia and cognitive decline. However, the mechanistic links between hyperhomocysteinemia and cognitive decline in AD are poorly understood. Several hypotheses have been proposed in the literature. The toxic effects of homocysteine could be mediated by N-homocysteinylation, a nonenzymatic reaction leading to the irreversible accumulation of N-homocysteinylated proteins. Finally, we detail some therapeutic trials targeting one-carbon metabolism in AD, notably vitamin B9 and B12 supplementation.
- 21 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (8) , 479
Cerebellar cognitive affective syndrome (CCAS) and [18F]-FDG PET findings in spinocerebellar ataxia type SCA27B
Background Spinocerebellar ataxia type 27B (SCA27B) is caused by ≥ 250 GAA repeat expansions in intron 1 of the FGF14 gene. While motor symptoms are well documented, cognitive manifestations remain insufficiently explored. The cerebellar cognitive affective syndrome scale (CCAS scale) provides a framework for assessing cognition. Methods We conducted a prospective study at Nancy University Hospital. The primary objective was to determine the prevalence of cerebellar cognitive affective syndrome. We subsequently characterized the cognitive profile using a standardized neuropsychological battery, evaluated quality of life, and examined the associations between CCAS score, GAA repeat length, motor severity, and age at onset. A [18F]-FDG PET metabolic analysis was performed, including individual visual analysis, followed by a whole-brain voxel-by-voxel comparison between SCA27B patients, healthy controls, and MSA patients. Results Seventeen patients with genetically confirmed SCA27B were included. Motor symptoms were moderate (mean SARA score: 7 ± 6.2/40). Definite cerebellar cognitive affective syndrome (≥ 3 failed subtests) was identified in 41% (7/17) of the patients. The comprehensive neuropsychological evaluation revealed mild-to-moderate cognitive impairment; across all cognitive functions tested, fewer than 12% of patients showed cognitive impairment, except for social cognition (23.6%). The PET scan showed preserved cerebellar metabolism in individual analyses (2 patients with hypometabolism). Whole-brain voxel-based analysis, when compared to healthy controls, identified 5 clusters of hypometabolism, with no hypermetabolism. Conclusion This study is among the first to investigate cognitive impairment in patients with SCA27B using the CCAS scale and comprehensive neuropsychological testing. A substantial prevalence of cerebellar cognitive affective syndrome was observed, even if the decrease of cerebellar metabolic was modest. These findings highlight the need for systematic screening of cognitive and nonmotor symptoms to improve multidisciplinary management.
- 21 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (8) , 479
Cerebellar cognitive affective syndrome (CCAS) and [18F]-FDG PET findings in spinocerebellar ataxia type SCA27B
Background Spinocerebellar ataxia type 27B (SCA27B) is caused by ≥ 250 GAA repeat expansions in intron 1 of the FGF14 gene. While motor symptoms are well documented, cognitive manifestations remain insufficiently explored. The cerebellar cognitive affective syndrome scale (CCAS scale) provides a framework for assessing cognition. Methods We conducted a prospective study at Nancy University Hospital. The primary objective was to determine the prevalence of cerebellar cognitive affective syndrome. We subsequently characterized the cognitive profile using a standardized neuropsychological battery, evaluated quality of life, and examined the associations between CCAS score, GAA repeat length, motor severity, and age at onset. A [18F]-FDG PET metabolic analysis was performed, including individual visual analysis, followed by a whole-brain voxel-by-voxel comparison between SCA27B patients, healthy controls, and MSA patients. Results Seventeen patients with genetically confirmed SCA27B were included. Motor symptoms were moderate (mean SARA score: 7 ± 6.2/40). Definite cerebellar cognitive affective syndrome (≥ 3 failed subtests) was identified in 41% (7/17) of the patients. The comprehensive neuropsychological evaluation revealed mild-to-moderate cognitive impairment; across all cognitive functions tested, fewer than 12% of patients showed cognitive impairment, except for social cognition (23.6%). The PET scan showed preserved cerebellar metabolism in individual analyses (2 patients with hypometabolism). Whole-brain voxel-based analysis, when compared to healthy controls, identified 5 clusters of hypometabolism, with no hypermetabolism. Conclusion This study is among the first to investigate cognitive impairment in patients with SCA27B using the CCAS scale and comprehensive neuropsychological testing. A substantial prevalence of cerebellar cognitive affective syndrome was observed, even if the decrease of cerebellar metabolic was modest. These findings highlight the need for systematic screening of cognitive and nonmotor symptoms to improve multidisciplinary management.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (2) , e200253
Involvement of the Superior Cerebellar Peduncles in GAA- FGF14 Ataxia
GAA-FGF14 ataxia (SCA27B) is a recently reported late-onset ataxia caused by a GAA repeat expansion in intron 1 of the FGF14 gene. After the clinical observation of superior cerebellar peduncle (SCP) involvement in some affected patients, we sought to verify the prevalence of this finding in our cohort and 4 additional independent cohorts of patients with SCA27B. We performed a retrospective review of the brain MRI scans of a total of 87 patients (median age at MRI 69 years; range 28-88 years) from different independent cohorts to assess the presence of SCP involvement, defined as abnormally high T2 signal along the SCP tract. We observed SCP involvement in 52 patients (52/87; 59.8%) from all the cohorts combined. The finding was replicated at rates ranging from 50% to 62.8% in the cohorts taken separately. SCP involvement in SCA27B is frequent. Its detection may facilitate the diagnostic process of patients with SCA27B.
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (2) , e200253
Open AccessInvolvement of the Superior Cerebellar Peduncles in GAA- FGF14 Ataxia
GAA-FGF14 ataxia (SCA27B) is a recently reported late-onset ataxia caused by a GAA repeat expansion in intron 1 of the FGF14 gene. After the clinical observation of superior cerebellar peduncle (SCP) involvement in some affected patients, we sought to verify the prevalence of this finding in our cohort and 4 additional independent cohorts of patients with SCA27B. We performed a retrospective review of the brain MRI scans of a total of 87 patients (median age at MRI 69 years; range 28-88 years) from different independent cohorts to assess the presence of SCP involvement, defined as abnormally high T2 signal along the SCP tract. We observed SCP involvement in 52 patients (52/87; 59.8%) from all the cohorts combined. The finding was replicated at rates ranging from 50% to 62.8% in the cohorts taken separately. SCP involvement in SCA27B is frequent. Its detection may facilitate the diagnostic process of patients with SCA27B.
- Open Access
- 9 December 2024
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 52 (5) , 868-870
Oculomotor Findings in Spinocerebellar Ataxia 27B: A Case Series
- 9 December 2024
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 52 (5) , 868-870
Open AccessOculomotor Findings in Spinocerebellar Ataxia 27B: A Case Series
- Open Access
- 11 April 2024
- Published by Elsevier in Revue Neurologique
- Vol. 180 (5) , 410-416
Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia
- 11 April 2024
- Published by Elsevier in Revue Neurologique
- Vol. 180 (5) , 410-416
Open AccessSpinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia
- 27 March 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179, S27
Le langage et les fluences verbales après stimulation cérébrale profonde des noyaux sous-thalamiques dans la maladie de Parkinson
- 27 March 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179, S27
Le langage et les fluences verbales après stimulation cérébrale profonde des noyaux sous-thalamiques dans la maladie de Parkinson
- 27 October 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 105, 15-18
Language and verbal fluency outcome after bilateral subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease
- 27 October 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 105, 15-18
Language and verbal fluency outcome after bilateral subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease